Faron Pharmaceuticals: Faron Pharmaceuticals Ltd: Faron appoints new CTO to strengthen late-stage development activities

Faron Pharmaceuticals OyAnnouncement

Today 07:00

Faron Pharmaceuticals Ltd | Company announcement | March 26, 2026 at 09:00:00
EET

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company, announces the appointment of Mr.
Heikki Jouttijärvi as the Company’s Chief Technical Officer (CTO).

Heikki Jouttijärvi brings decades of experience in biopharma manufacturing,
supply chain management and commercial operations. Most recently, he has been
the SVP of Commercial Business Operations at Adverum Biotechnologies, Inc that
was acquired by Eli Lilly. Prior to that Mr. Jouttijärvi has held various
global roles at Menlo Therapeutics, Inc and Santen Pharmaceutical Company,
Ltd. He holds a M.Sc degree in Pharmacy from the University of Helsinki.

“We are extremely happy to welcome Heikki as a part of the Faron team. His
wealth of experience with commercial operations, manufacturing and supply
chain management with late-stage and approved drugs is incredibly valuable for
us as we progress with bexmarilimab to the announced Phase IIb trial in HR
MDS”, comments Dr. Juho Jalkanen, CEO of Faron.

“I am honored to join the Faron team at this exciting point in time in the
development of bexmarilimab. I have been amazed by the resilience and
excellent hard work done with bexmarilimab to date and I am humbled to be able
to join the program at this stage. We look forward to advance the program to
the benefit patients, whom deserve our ultimate commitment”, says Mr.
Jouttijärvi, newly appointed CTO of Faron Pharmaceuticals.

For more information, please contact:

+-------------------------------------+--------------------------------------+
| IR Partners, Finland                |                                      |
| (Media)                             | +358 50 553 9535 / +44 7 469 766 223 |
|                                     | kare.laukkanen@irpartners.fi         |
| Kare Laukkanen                      |                                      |
+-------------------------------------+--------------------------------------+
| FINN Partners, US                   | +1 847 791-8085                      |
| (Media)                             | alyssa.paldo@finnpartners.com        |
| Alyssa Paldo                        |                                      |
+-------------------------------------+--------------------------------------+
| Cairn Financial Advisers LLP        | +44 (0) 207 213 0880                 |
| (Nominated Adviser and Broker)      |                                      |
| Sandy Jamieson, Jo Turner           |                                      |
+-------------------------------------+--------------------------------------+
| Sisu Partners Oy                    | +358 (0)40 555 4727                  |
| (Certified Adviser on Nasdaq First  | +358 (0)50 553 8990                  |
| North)                              |                                      |
| Juha Karttunen                      |                                      |
| Jukka Järvelä                       |                                      |
+-------------------------------------+--------------------------------------+

About bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed
to overcome resistance to existing treatments and optimize clinical outcomes,
by targeting myeloid cell function and igniting the immune
system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on
macrophages leading to tumor growth and metastases (i.e. helps cancer evade
the immune system). By targeting the Clever-1 receptor on
macrophages, bexmarilimab alters the tumor microenvironment, reprogramming
macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1)
one, upregulating interferon production and priming the immune system to
attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The company’s lead asset, bexmarilimab, is a novel
macrophage-guiding immunotherapy being investigated in multiple oncology
settings. Further information is available at www.faron.com
(http://www.faron.com/).

Forward-Looking Statements 

This press release contains certain forward-looking statements relating to the
business of Faron Pharmaceuticals. In addition, even if the actual results or
development of Faron Pharmaceuticals are consistent with the forward-looking
statements contained in this press release, those results or developments of
Faron Pharmaceuticals may not be sustained in the future. In some cases, you
can identify forward-looking statements by words such as “could,” “should,”
“may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,”
“targets,” or similar words. These forward-looking statements are based
largely on the current expectations of Faron Pharmaceuticals as of the date of
this press release and are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from any future results, performance
or achievement expressed or implied by these forward-looking statements. In
particular, the expectations of Faron Pharmaceuticals could be affected by,
among other things, uncertainties and delays involved in the development of
product candidates, unexpected clinical trial results, unexpected regulatory
actions or delays, competition in general, currency fluctuations, inflation,
changes in tariff policies, political or macroeconomic developments, and the
ability to obtain or maintain patent or other proprietary intellectual
property protection. Success in preclinical studies or earlier clinical trials
may not be indicative of results in future clinical trials. In light of these
risks and uncertainties, there can be no assurance that the forward-looking
statements made in this press release will in fact be realized. Faron
Pharmaceuticals is providing this information as of the date of this press
release and disclaims any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise